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Abstract
The fourth scientific workshop of the European Crohn's and Colitis Organization (ECCO) focused on the
relevance of intestinal fibrosis in the disease course of inflammatory bowel disease (IBD). The
objective was to better understand the pathophysiological mechanisms of intestinal fibrosis, to
identify useful markers and imaging modalities of fibrosis in order to assess its presence and
progression, and, finally, to point out possible approaches for the prevention and the treatment of
fibrosis.
The results of this workshop are presented in three separate manuscripts. This first section
describes the most important mechanisms that contribute to the initiation and progression of
intestinal fibrosis in IBD including the cellular and molecular mediators, the extracellular matrixerology Unit, Department of Life, Health and Environmental Sciences, University of L'Aquila, Piazza S.
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1148 G. Latella et al.molecules and matrix metalloproteinases/tissue inhibitors of metalloproteinases-system, the
microbiota products, the role of fat, genetic and epigenetic factors, as well as the currently
available experimental models. Furthermore, it identifies unanswered questions in the field of
intestinal fibrosis and provides a framework for future research.
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• Intestinal fibrosis is common in IBD;
• Fibrosis is defined by excessive ECM;
• Fibrosis occurs as a consequence of inflammation
and follows its distribution;
• Inflammation is necessary to trigger fibrosis, but
may have a minor role in its progression;
• Therapeutic control of intestinal inflammation
may not affect fibrogenesis;
• Fibrosis is a chronic and progressive process acting
through complex cell/matrix/cytokine and growth
factors interactions, but may be reversible;
• Understanding of themechanisms behind intestinal
fibrosis may pave the way for new anti-fibrotic
agents.1. Introduction
Fibrogenesis is a “physiological process” triggered by inflam-
mation that may lead to tissue repair or fibrosis depending on
the balance between production and degradation of extracel-
lular matrix (ECM) proteins.1 Fibrosis occurs when regenera-
tion and repair fail to restore normal tissue architecture and
can lead to organ malfunction and death. Although fibrosis is
increasingly recognized as a problem, there are few, if any,
treatment strategies available. Fibrosis is a common problem
in inflammatory bowel disease (IBD) but which factors trigger
chronicity and promote fibrosis is not known.2,3
Inflammation is necessary for fibrosis, but it subsequently
plays a minor role in its progression and anti-inflammatory
treatment in IBD may not prevent fibrosis once excessive ECM
deposition has started.4 Mechanisms that regulate fibrosis,
therefore, appear to be distinct from those regulating
inflammation. Fibrosis, however, follows the distribution of
inflammation. In ulcerative colitis (UC), ECM deposition is
restricted to the colonic mucosal and submucosal layers. In
CD, fibrosis can involve the full thickness of the bowel and
result in luminal narrowing. Intestinal fibrosis, however,
displays significant variability among IBD patients suggesting
that fibrosis susceptibility may have a genetic component
with conditioning by environmental and intestinal microbial
factors.2
Despite therapeutic advances in IBD, none prevent, nor
reverse, established strictures.4 This implies that controlling
inflammationmay only partially affect fibrosis. The lack of any
anti-fibrotic drugs is partly due to the main, and specific
cellular and molecular fibrosis pathways remaining unidenti-
fied. New and improved preclinical animal fibrosis IBD models
are thus needed.5 Anti-fibrotic drug development is also
hindered by the unpredictable evolution of fibrosis as a clinical
benefit may only be observed after prolonged treatment
making clinical trials long and expensive.
To design effective anti-fibrotic drugs, fibrosis needs to be
viewed as a pathological process distinct from inflammation.
Understanding the mechanisms leading to intestinal fibrosis
may thus pave the way for new anti-fibrotic agents.4 In this
review, we describe the most important mechanisms that
contribute to the initiation and progression of intestinal IBD
fibrosis including the cellular and molecular mediators, the
ECM molecules and matrix metalloproteinases (MMPs)/tissue
inhibitors of metalloproteinases (TIMPs)-system, the micro-
biota products, the role of fat, genetic and epigeneticfactors, as well as the currently available experimental
models.2. Cellular and Molecular Mediators of
Intestinal Fibrosis
Intestinal fibrosis is no longer considered inevitable and
irreversible.1,2 Myofibroblast activation is a common feature
in fibrosis and research of the innate and adaptive immune
responses in IBD participate in the differentiation/activation of
myofibroblasts.2 The Th17-type immune response is proinflam-
matory/profibrotic. Th2-type immunity, defined by interleukin
(IL)-4, -5 and -13 production is also fibrogenic with IL-13 being
the dominant mediator. By contrast, Th1-type immunity
expressing interferon-γ (IFN-γ) has anti-fibrotic activity. A
detailed overview of how the immunemediators affect fibrotic
disease of other organs, including liver, lung, skin and kidney,
has been recently published and shall not be covered further
here.1
While in other organs the source of ECM-producing
myofibroblasts is restricted to a few cell types, in the intestine
multiple cell types may become activated myofibroblasts.2,4
These cells derive not only from resident mesenchymal cells
(fibroblasts, sub-epithelial myofibroblasts [SEMFs] and smooth
1150 G. Latella et al.muscle cells [SMCs]) but also from epithelial and endothelial
cells (via epithelial [EMT]/endothelial–mesenchymal transi-
tion [EndoMT]), stellate cells, pericytes, and bone marrow
stem cells2,4 (Fig. 1). ECM-producing cells are activated by
paracrine signals, autocrine factors, and pathogen-associated
molecular patterns (PAMPs) derived frommicroorganisms that
interact with pattern recognition receptors (PRRs) such as
toll-like receptors (TLRs).2 Myofibroblasts are also activated
by products derived from injured cells, the ‘so-called’
damage-associated molecular patterns (DAMPs) including
DNA, RNA, ATP, high-mobility group box proteins (HMGB),
microvesicles, and fragments of ECM molecules.2
All intestinal ECM-producing cells act synergistically and
are controlled by numerous molecular mediators1,4 (Table 1).
The most important include transforming growth factor-β
(TGF-β), activins, connective tissue growth factor (CTGF),
platelet-derived growth factor (PDGF), insulin-like growth
factor (IGF-1&2), epidermal growth factor (EGF), endothelin
(ET-1, -2, -3), various cytokines, products of oxidative stress,
components of the renin–angiotensin system (RAS), angiogen-
ic factors (e.g. vascular endothelial growth factor-VEGF) and
mammalian target of rapamycin (mTOR).4 Soluble factors with
anti-fibrotic properties have also been identified including
peroxisome proliferator activated receptors (PPARs), IFN-α,
IFN-γ, IL-7, IL-10, IL-12, Smad7, adiponectin and nitric oxide
(NO).
Although the TGF-β/Smad pathway represents the major
driving force of fibrosis, several pro-fibrogenic and anti-
fibrogenic molecules seem to interact directly with the
TGF-β/Smad pathway (Fig. 2). The effect of these mediators
on the TGF-β/Smad ‘core pathway’ have been extensively
discussed in a recent review.4 The pharmacological modula-
tion of ECM deposition by reducing ECM-producing cell
activation and/or by modulation of specific molecular
mediators could thus modify intestinal fibrosis.1,2,4Figure 1 Pathogenetic steps of intestinal fibrosis in IBD. ROS = react
subepithelial myofibroblasts; ICC = intestitial cells of Cajal; EMT =
mesenchimal transition; ECM = extracellular matrix.Blockade of TGFβ signalling, either at the extracellular, or
intracellular, level offers a strategy to prevent/treat fibro-
sis.1,4 Since TGFβ, however, is also involved in cellular
differentiation, proliferation, transformation and immuno-
regulation, its blockade is problematic as TGFβ, Smad2 and
Smad4 disruptions are lethal. Targeting of individual intracel-
lular mediators, however, could lead to the selective blockade
of TGFβ fibrotic responses without involving physiologically
vital TGFβ responses (Fig. 3). Disrupting Smad3 results in mice
that survive to adulthood and also confers resistance to tissue
fibrosis.4 Hepatic growth factor (HGF), bone morphogenetic
protein (BMP-7) and decorin are three natural inhibitors of the
TGFβ/Smad pathway and demonstrate anti-fibrotic effects.
In addition to the most common pro-fibrotic mediators
including several growth factors, cytokines, chemokines and
reactive oxygen species (ROS), new inducing and modulators
factors of fibrosis are emerging (Table 1). These include RAS,
integrins, mTOR, PPARs, PAMPS, TLRs, DAMPs, ECM fragments,
Hedgehog (Hh) signalling and Wnt/β-catenin and Klotho
pathways, receptor for advanced glycation endproducts
(RAGE), Notch signalling pathway, microRNAs (miRNAs), as
well as endoplasmic reticulum (ER) stress and telomere
shortening.2.1. Renin–angiotensin system (RAS)
The RAS regulates cell growth, differentiation, proliferation
and apoptosis, ROS generation, cytokine expression, endothe-
lial cell activation, inflammation, ECM production and
fibrosis.6 All components of the RAS exist in the intestine.
Angiotensin II (ANGII), the principal effector of RAS, partici-
pates in fibrosis through the regulation of the inflammatory/
fibrotic processes. ANGII is increased in CD intestine. Intestinal
fibrosis is significantly improved, or even reversed, byive oxygen species; SMCs = smooth muscle cells; SEMFs = intestinal
epithelial-to-mesenchymal transition; EndoMT = endothelial-to-
Table 1 Molecules involved in intestinal fibrosis.
Fibrogenic Anti-fibrogenic
- Transforming growth factor-β (TGF-β)
- Smad2/3 proteins
- Activin A
- Connective tissue growth factor (CTGF)
- Platelet derived growth factor (PDGF)
- Insulin-like growth factors (IGF-I and II)
- Epidermal growth factor (EGF)
- Basic fibroblast growth factor (bFGF)
- Cytokines (IL-1β, IL-4, IL-6, IL-13, IL-17, IL-21,
IL-22, IL-23, IL-33, TNF-α)
- CC- and CXC-chemokines (CCL2, CCL3, CCL4, CCL20)
- Reactive Oxygen Species (ROS)
- Integrins (αVβ6, αVβ8)
- Mammalian Target Of Rapamycin (mTOR)
- PAMPs and TLRs (TLR2&4 ligands)
- DAMPs (DNA, RNA, ATP, HMGB1, uric acid, fragments of ECM)
- Hedgehog (Hh) signalling pathway
- Wnt– β-catenin signalling pathway
- Advanced glycation endproducts receptor (RAGE)
- Notch signalling pathway
- MicroRNAs (miRNAs)
- Endoplasmic reticulum (ER) stress
- Vascular endothelial growth factor (VEGF)
- Endothelins (ET-1)
- Angiotensin Converting Enzyme (ACE)
- Angiotensin-II (AT-II)
- Norepinephrine
- Thrombospondin-1,2
- Leptin
- Tissue Inhibitor of Metalloproteinases (TIMPs)
- Peroxisome Proliferator Activator Receptor-γ (PPAR-γ)
- Interferon-α (INF-α)
- Interferon-γ (INF-γ)
- IL-7, IL-10, IL-12
- Smad7 protein
- PGE2
- Hepatocyte growth factor (HGF)
- Adiponectin
- Klotho
- Nitric Oxide (NO)
- Relaxin
- Matrix Metalloproteinases (MMPs)
1151Intestinal fibrosis in IBDAngiotensin converting enzyme (ACE) inhibitors and AT1
receptor antagonists, findings that closely correlate to
reduced TGF-β1 and CTGF expression.7
2.2. Integrins
Integrins regulate cell and ECM interactions and influence
fibrosis.4 In normal conditions αvβ6 integrin is not
expressed, but is up-regulated and co-localises with TGF-β
following tissue injury.8 αvβ6 activates latent TGF-β, while
various genetic and pharmacologic interventions targeting it
reduce TGF-β1 activation and fibrosis.9 Inhibitors of αvβ6
significantly reduce tissue levels of pro-fibrogenic tran-
scripts, including procollagen α1, α-SMA, TGF-β1, TGF-β2,
CTGF, TIMP-1 and αvβ6 itself. Inhibition αvβ6 integrin could
thus impact fibrosis, through local TGF-β inhibition without
affecting vital homeostatic TGFβ roles.4
2.3. Mammalian target of rapamycin (mTOR)
mTOR, a phosphatidylinositol 3-kinase-related kinase, forms
at least two distinct complexes.10 The mTOR complex 1
(mTORC1) is composed of mTOR, GβL and Raptor and controls
protein synthesis, cell growth/proliferation, autophagy, an-
giogenesis and fibrosis. The mTOR complex 2 (mTORC2)
consists of mTOR, GβL and Rictor and is involved in cellproliferation and survival, metabolic regulation and actin
cytoskeleton organization. mTOR signalling is activated by
hormones, growth factors, amino acids, stress and alterations
in cellular energy status. mTOR inhibitors (mTORis) have
anti-fibrotic activities, reduce fibroblast/myofibroblast num-
bers and down-regulate pro-fibrogenic cytokine production.
Defective autophagy and angiogenesis may cause fibrosis.
Control of angiogenesis and lymphangiongenesis, might
improve fibrosis, particularly due to the connection between
vascular remodelling and fibrogenesis in chronic inflamma-
tion.11 VEGF expression is increased in IBD and its blockage
reduces fibrosis in animal models.
mTOR regulates hypoxia-inducible factor (HIF)1-α, VEGF and
angiopoietin-2 expression, the main driving factors of neo-
angiogenesis. TGFβ/Smad3 also activates mTORC1 and pro-
motes collagen production by increasing HIF-1α and mTORC1
inhibition prevents TGF-β-inducedHIF expression and fibrosis.12
The combined immunosuppressive and anti-fibrotic action of
mTOR inhibitors like rapamycin, and its analogues, sirolimus
and everolimus, are thus potential treatments in CD fibrosis.2.4. Peroxisome proliferator activator receptors
(PPARs)
PPARs are nuclear receptors which regulate gene transcrip-
tion.13 PPAR-γ is present in colorectal mucosa and in
Figure 2 Relationship among several pro-fibrotic and anti-fibrotic mediators in the development of fibrosis. IL-13 = Interleukin-13;
CCL2 = monocyte chemoattractant protein-1 (MCP1); CCL3 = macrophage inflammatory protein-1 (MIP1); TGF-β = transforming growth
factor-β; CTGF = connective tissue growth factor; PDGF = platelet derived growth factor; IGF-I = insulin-like growth factors I;
TLR-2,-4 = Toll-like receptor-2,-4; miRNA = microRNA; EGF = epidermal growth factor; bFGF = basic fibroblast growth factor; ETs =
endothelins; ACE = angiotensin convertingenzyme; AT-II = angiotensin-II; mTOR = mammalian target of rapamycin; PPAR-γ = peroxi-
some proliferator activator receptor-γ; INF-α&β = interferon-α&β; HGF = hepatic growt factor; ECM = extracellular matrix.
Figure 3 Interaction between profibrotic transforming growth factor-β (TGF-β) and anti-fibrotic peroxisome proliferator activator
receptor-γ (PPAR-γ) factors: need to identify and selectively modulate trasduction and transcription signalings of ECM synthesis/
degratation without to affect other physiological pathways.
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1153Intestinal fibrosis in IBDadipocytes, monocytes, macrophages, dendritic, B and T
cells. It modulates adipocyte differentiation, glucose ho-
meostasis, lipid metabolism, inflammatory/immune pro-
cesses and fibrosis. PPAR-γ activation strongly correlates
with the TGF-β/Smad pathway as it directly antagonises
Smad3, or down-regulates CTGF expression (Fig. 2).14 It also
prevents the increase in profibrotic MMP-2, MMP-9, TIMP-1,
PDGF and leptin activities.15,16 Reduced PPARs expression
induces increased collagen production and fibrosis progres-
sion, whereas its overexpression prevents fibrosis.17 PPAR-γ
has received particular attention in recent years as its
activation, both by natural and synthetic agonists, attenu-
ates fibrosis in several organs including the intestine, and
these anti-fibrotic effects are abolished by PPAR-γ selective
antagonists.13,18 PPAR-γ is thus an innate protector against
excessive fibrogenesis and a potential anti-fibrotic target in
IBD.2.5. PAMPs and TLRs
Many fibrotic disorders have an infectious aetiology.19 In IBD,
luminal bacteria are pathogenic and express PAMPs that
activate immune and non-immune cells. PAMPs include lipo-
polysaccharide (LPS), bacterial DNA, and double-stranded RNA,
and these bind to PRRs like TLRs.2
TLRs act as microbial product sensors that trigger host
defense and activate immune and both pro-inflammatory and
pro-fibrotic gene expression. TLR activation is pivotal in IBD,
suggesting that TLR over-expression could underlie abnormal
host reactions to commensal bacteria in IBD. CD patients with
antibodies directed against microbial peptides develop earlier
fibrostenotic disease.20 This defective immune tolerance to
commensal bacteria suggests that an aberrant innate immune
response is involved in intestinal fibrogenesis.
TLR expression in non-immune cells is a key event leading
to fibrosis. Increased expression of TLR2, -3, -4, -6 and -7Figure 4 Genetic variants and immune responses in Crohn's disea
surgery. NOD2 = nucleotide oligomerization domain 2; TLRs = toll-l
antibodies; Ags = antigens; ASCA = anti-Saccharomyces cerevisiae ant
membrane porin C of Escherichia coli; CBir1 = bacterial flaggelin cBir1occurs in CD and promote fibroblast differentiation into
myofibroblasts and ECM expression.21
The major NOD2 polymorphisms associated with CD
produce defects in host defense against invading bacteria
leading to persistent intracellular infection.20 NOD2 is
expressed by Paneth cells with a correlation between
NOD2 variants and down-regulation of mucosal α-defensin.
NOD2 gene variants in CD with/without variants of TLRs
(TLR4) or ATG16L1 have an increased risk of small bowel
(SB) fibrostenosis20 (Fig. 4).
2.6. DAMPs
Activation of immune and non-immune cells can occur by
products from injured cells, the DAMPs that promote inflam-
mation. DAMPS include a wide range of products (DNA, RNA,
ATP, HMGB1, ECM fragments, interleukins etc) which cause
sterile inflammation, but whether DAMPs promote fibrosis is
unclear.2 One of the best-characterized DAMPs is the HMGB1.
Ethyl pyruvate inhibits HMGB1 release and decreases inflam-
mation, ameliorates colitis and reduces intestinal cytokine
production in IL-10−/− mice, while HMGB1 activation of the
induced RAGE promotes NF-κB and MAP kinase signalling,
resulting in inflammation.22 The HMGB1/RAGE pathway regu-
lates metabolism and autophagy in experimental colitis and
HMGB proteins function as universal sentinels for nucleic
acid-mediated innate immune responses.23
2.7. ECM components
ECM regulates inflammation, healing and fibrosis.1 Intestinal
ECM acts as a reservoir for pro-fibrotic factors, cytokines and
chemokines. TNF-α, TGF-β and bFGF interact with various ECM
moieties, while ECM fragments bind to, and activate, TLR2 and
TLR4. Fibrin, collagen IV and laminin fragments, modulate cell
migration and proliferation, while fibrin and fibronectinse patients may predict the risk for fibrostenosis phenotype and
ike receptors; ATG16L1 = autophagy-related-16 L1 gene; Abs =
ibodies; I2 = pseudomonas-associated sequence I2; OmpC = outer
.
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myofibroblast differentiation and induces pro-inflammatory/
fibrotic cytokine expression and MMP secretion.242.8. Hedgehog signalling
The Hedgehog (Hh) signalling pathway regulates fibrosis and
progenitor cell proliferation and differentiation. It is
pro-fibrotic and promotes myofibroblast activation, EMT,
MMP release, TGF-β1 and ECM production.25 Conversely, Hh
signalling inhibition is potently anti-fibrotic in preclinical
models of fibrosis.262.9. Wnt/β-catenin
The Wnt-β-catenin signalling pathway regulates cell growth,
tumourigenesis and is activated in fibrosis. Activation of
Wnt-β-catenin signalling promotes EMT and is required for
TGF-β-mediated fibrosis.27 Involvement of the α3β1 integrin
occurs in the crosstalk between TGF-β1 and Wnt signalling.
TGF-β stimulates canonical Wnt signalling in a p38-dependent
manner by decreasing the expression of the Wnt antagonist
Dickkopf-1 (DKK-1). In addition, hypermethylation of DKK1
promotors lead to aberrant Wnt signalling representing a link
between epigenetic alterations and Wnt signalling in fibro-
sis.28 Wnt signalling increases ECM synthesis, T cell transmi-
gration and regulates MMP-2, -7 and -9. Inhibition of Wnt-β-
catenin signalling reverses fibrosis.2.10. Klotho
Klotho family of membrane proteins function as obligate
co-receptors for some fibroblast growth factors (FGFs).29
The extracellular domain of Klotho protein is subject to
ectodomain shedding and is released into circulation to act as
an endocrine factor. Unlike membrane Klotho, which func-
tions as a co-receptor for FGF23 to modulate FGF23 signal
transduction, soluble Klotho is a multifunction protein present
in biological fluids and impacts aging, energymetabolism,Wnt
signalling inhibition, anti-oxidation, ion transport, RAS antag-
onism and fibrosis inhibition.30
Secreted Klotho protein directly binds to the type-II TGF-β
receptor and inhibits TGF-β1 receptor binding, TGF-β1
signalling and TGF-β1-induced EMT. In addition, secreted
Klotho inhibits the Wnt and IGF-1 signalling that promotes
EMT. Overexpression of Klotho abolished TGF-β1-induced
fibrosis.302.11. RAGE
This receptor for advanced glycation end products (AGEs) is
fibrogenic, promotes EMT and ECM accumulation, increases
activated myofibroblast numbers and up-regulates αSMA.31 In
IBD, high RAGE expression correlates with disease activity and
induces pro-inflammatory mediators.32 Ligands inhibiting
RAGE, by competing with AGE, could be therapeutic in IBD
fibrosis.2.12. Notch signalling
The Notch signalling pathway is essential to normal embry-
onic development, cellular proliferation and differentia-
tion.33 Four Notch receptors and five ligands have been
identified in mammals. Notch signalling is activated through
the interaction of a Notch receptor with a ligand expressed
on adjacent cells. The aberrant activation of this pathway
induces fibrosis.34 Blocking Notch signalling with c-secretase
inhibitors significantly attenuates fibrosis and decreases
snail, vimentin, TGF-β1 and EMT.34
Notch signalling, particularly Notch1, cooperates with
TGF-β in regulating FoxP3 expression during T regulatory
cell (Treg) generation. Tregs are linked to fibrosis amelio-
ration, although its specific role in fibrogenesis is less clear:
it is plausible that Tregs could suppress Th17- and Th
2-driven fibrosis.35
2.13. miRNAs
miRNAs are small, noncoding RNAs of 18–25 nucleotides that
regulate gene and protein expression by repressing specific
target genes post-transcriptionally. Over 80 miRNAs are
implicated in fibrosis by modulating ECM remodeling, cell
adhesion, inflammation, angiogenesis and EMT.36 miRNA-21
and miRNA-29 promotes fibrosis by regulating TGF-β1/Smad
and MAP kinase signalling, as well as CTGF and collagen
expression. miRNA-192, miRNA-216a and miRNA-217, as
miRNA-21, are key triggers of TGF-β and Smad3-driven fibrosis
and miRNA-200a and miRNA-200b are involved in CD fibrosis.37
Some miRNAs like miRNA let-7d, miRNA-133, miRNA-30,
miRNA-150, miRNA-194, and miRNA-200a are constitutively
expressed in healthy tissues but down-regulate in fibrosis,
suggesting an anti-fibrotic role. Specific miRNAs down-regulate
Smad-3 activity and ECM expression, and prevent TGFβ-
dependent EMT. miRNA-200 regulates TGF-β/Smad-induced
EMT by controlling the Zinc finger E-box-binding homeobox 1
and 2 (ZEB1 and 2).38 The miRNA changes in IBD and their
specific role in fibrosis deserve further and more exhaustive
investigations.
2.14. Endoplasmic reticulum (ER) stress
ER stress leading to apoptosis of key structural cells may
regulate fibrosis.39 Excess accumulation of unfolded, or
misfolded proteins in the ER activates cellular stress path-
ways. ER stress is common in IBD.40 Genetic and environmental
factors affect intestinal ER stress and inflammation.40 Genetic
factors include either primary ER Stress (XBP1, AGR2,
ORMDL3) or secondary ER stress (HLAB27, Mucins, ATG16L1).
Environmental factors include bacteria, dietary and drugs.
Induction of ER stress activates several EMT-related pathways,
including TGF-β/Smads, Wnt/β-catenin, and Src.41 A better
understanding of the mechanisms of ER stress could help in
fibrosis prevention.
2.15. Telomere shortening
Telomere shortening impacts on pulmonary fibrosis and
occurs with mutations in gene encoding telomerase reverse
1155Intestinal fibrosis in IBDtranscriptase, an enzyme crucial to the maintenance of
telomere length.1 Pro-fibrotic mediators, like TGF-β1 and
ROS, also participate in telomere shortening suggesting a
vicious cycle among pro-fibrotic mediator production,
impaired telomerase activity and fibrosis.42 Unfortunately,
data on telomere shortening in IBD are lacking.Key points
• Myofibroblasts derive from mesenchymal, epi-
thelial, endothelial, and stellate cells, pericytes,
and bone marrow stem cells;
• ECM-producing cells act synergistically and are
under numerous biological mediator control;
• Blockage of selective signalling pathways can
prevent/reverse intestinal fibrosis.
Questions
• What are the cellular triggers leading to fibrosis
progression?
• What is the main source of myofibroblasts in
intestinal fibrosis?
• What are the main mediators of myofibroblast
activation?
• What are the specific molecular markers of
activated myofibroblasts?
• Which factors determine the switch from inflam-
matory to fibrosing disease?
• Can timing, concentration and the source of the
main pro-fibrotic mediators affect their contri-
bution to tissue remodelling/fibrosis?
• Is the simultaneous action of pro-fibrotic medi-
ators relevant to fibrogenesis?
• Which factors represent the driving force (“core
pathway”) of intestinal fibrosis?
• Which factors with anti-fibrotic properties play a
critical role in intestinal fibrosis?3. ECM molecules and MMP/TIMP system
Fibrogensis hinges on the balance between ECM deposition
and degradation. If deposition outstrips degradation then
fibrosis may occur, but if this balance can be modified then
healing may proceed without fibrosis.3,43
3.1. Extracellular matrix (ECM)
The intestinal ECM is comprised of structural proteins,
particularly the collagens, specialized proteins, like vitronectin
and fibronectin, andmatricellular proteins, such as osteopontin
and trombospondin (Table 2). Chronic intestinal inflammation
leads to tissue damage with an increase in ECM turnover. ECM
degradation is mediated by MMPs and the fine balance between
MMPs and TIMPs appears to be disturbed in IBD.43 It is unclear,
however, which specific MMPs and TIMPs are involved in fibrosis
and how they are regulated.3.2. MMP/TIMP system
MMPs are zinc- and calcium-dependent ECM degrading
endopeptidases and collectively can degrade all ECM
proteins. In addition, MMPs can proteolytically activate,
or degrade, a variety of non-matrix substrates, including
chemokines, cytokines, growth factors, and junctional
proteins, which are usually secreted in an inactive
preform.
Depending on substrate specificity, amino acid similarity,
and identifiable sequencemodules, the MMPs can be classified
into: collagenases, gelatinases, stromelysins, matrilysin,
membrane-types and others44 (Table 2). MMPs are regulated
by two endogenous inhibitors, α2-macroglobulin and the
TIMPs.
MMPs are up-regulated in colitis models and IBD.43 MMP-9
and -3 are associated with mucosal damage and fistulae in
CD, MMP-1, -3, and -13 with intestinal ulcers and MMP-10
and -11 with epithelial dysfunction. In fibrosis, MMP-1 and
collagen I, but not MMP-3 or collagen III, levels were
elevated in the TNBS murine fibrosis model which parallel
that in fibrosed CD.45 Mucosa overlying strictured fibro-
stenosing CD demonstrate higher TIMP-1 levels and lower
Smad7, MMP-12 and -3 expression than from mucosa
overlying non-strictured areas.46
Soluble mediators that are present in inflamed IBD
modulate MMP and TIMP expression.2,4 TGF-β1 increases
collagen secretion, decreases MMP-1 and increases
TIMP1 production resulting in a net increase in collagen
deposition. PDGF and IGF-1 also increase collagen production,
but do not alter TIMP-1. IGF-1 decreases MMP-1 while PDGF
increases its production. By contrast, enhanced cyclooxygen-
ase (COX)-2 activity can block the pro-fibrogenic effects of
TGF-β1 in SMCs and inhibit basal, and stimulated, levels of
TIMP while inducing MMP secretion by macrophages. Activa-
tion of COX-2 also increases prostaglandin (PG)-E2 production
and an increase in PGE2 decreases fibroblast and SMC
proliferation.
Indomethacin, a non-specific COX inhibitor, induces
intestinal inflammation and fibrosis in the TNBS mouse
model.47 In this model PGE2 decreased intestinal inflam-
mation and fibrosis and in PMA ± Indomethacin-treated
murine and human colonic fibroblasts, PGE2 significantly
decreased ECM deposition by decreasing TGFβ, collagen
and TIMP expression, while increasing MMP expression.
TIMPs inhibit MMPs.48 TIMP-1 and -3 are inducible, while
TIMP-2 is constitutively expressed. A critical balance between
MMPs and TIMPs maintains normal ECM homeostasis. An
imbalance may enhance ECM deposition and fibrosis. Further-
more, TIMPs affect signalling and angiogenesis and TIMP-1
expression inversely correlates with pro-inflammatory cyto-
kine production, mucosal injury and disease activity.48
Increased TIMP-1 levels occur in CD strictures.46
TIMP-3 is tightly bound to the surrounding matrix, is
detected in normal and inflamed intestine and is expressed
below ulcers and in the LP surrounding damaged crypts. The
ratio between MMP-1/TIMP-1 and MMP-3/TIMP-1 is increased
in inflamed IBD tissue and MMP-3 levels are increased in
fibroblasts and mononuclear macrophage-like cells with
concomitant low levels of TIMP-1, TIMP-2 and TIMP-3 in
intestinal CD fistulae.49 TGFβ1 down-regulates MMP and
enhances TIMP-1 expression.
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MMPs and TIMPs are central to ECM turnover and actively
regulate inflammation and remodelling. The net effect,
however, is not dependent only on the MMP/TIMP balance,
as functional receptors that mediate downstream signalling of
TIMPs may provide additional perspectives for consideration
when examining the role of MMPs and TIMPs in fibrosis.Key points
• ECM components are active players in fibrosis;
• MMP/TIMP balance alterations are observed in
intestinal fibrosis;
Questions
• How do ECM components contribute to fibrosis?
• What are the main sources of MMPs and TIMPs?
• Which MMPs and TIMPs are most important?
• How do MMPs and TIMPs contribute to intestinal
fibrosis?4. Microbiota products
The whole gut microbiome can be considered a true organ
that is geared up for protecting our health and well-being
and is amenable to modulation. Co-evolution of host and
bacteria results in a symbiotic relationship, where the
survival of harboured microbiota and human host is
interdependent.Table 2 ECM molecules and MMP/TIM-system in intestinal fibros
ECM molecules
Collagens
Glycoproteins
Proteoglycans
Proteins modifying ECM
Matrix Metalloproteinases
Tissue inhibitor of metalloproteinasesWhile the microbiota is part of the internal gut microenvi-
ronment, this organ is subject to external macroenvironmental
influences. The established concept is that all environmen-
tal elements may influence disease, and several environ-
mental factors can influence immune responses leading to
fibrosis. Given the enormity and diversity of the external
environment, new tools and approaches are needed to
evaluate the impact of the “exposome” on intestinal
disease and fibrosis.2
The dominant mucosa-associated microbiota appears dif-
ferent from luminal faecal microbiota but is highly conserved
in different intestinal segments. Bacteria residing in the
mucous layer form a protective ‘living wallpaper’ against
exogenous bacteria through colonisation resistance. Once the
gastrointestinal mucus layer is disrupted, bacteria directly
contact with epithelial, dentritic, lymphocitic and stromal
cells and endanger mucosal homeostasis.
Chronic alteration of the intestinal mucosal barrier and
microbiota may be critical in IBD pathogenesis, as well as in
fibrosis.50,51 Molecular evaluation allows for the definition of
“normal” microbiota, or normobiosis and exploring the
dysbiosis in disease and its role in fibrosis.
4.1. Microbiota in IBD
Dysbiosis in IBD is characterized by increased bacterial
density at the mucosal level, increased proportions of
immuno-agressive commensals, reduced proportions of
anti-inflammatory commensals, and increased proportions
of proteins that promote autoimmunity.51 Such dysbiosis
creates a vicious circle favouring chronic inflammation. F.
prausnitzii has anti-inflammatory properties which induces
high IL10/IL12 cytokine release, reduces IL-1β and induces
IL-8, and abolishes TNF-α induced NF-κB activity. The
gut microbiota is involved in intestinal fibrogenesis byis.
• Fibrillar Type Collagens I - III - V
• Non-Fibrillar Collagen Type IV
• Laminin
• Entactin/nidogen
• Fibronectin/vitronectin
• Tenascin
• Sparc/BM40
• Thrombospondin/osteopontin
• Glycosaminoglycans (hyaluronic acid)
• Heparan sulfate
• Chondroitin sulfate
• Perlecan
• Collagenases (MMP-1, -8, -13, -18)
• Gelatinases (MMP-2, -9)
• Stromelysins (MMP-3, 10, -11)
• Matrilysin (MMP-7)
• Elastase (MMP-12)
• Membrane types (MT-1,-2,-3,-4,-5,- 6-MM; namely MMP-14,
MMP-15, MMP-16, MMP17, MMP-24, MMP-25, respectively)
• Others (MMP-19, -20, -21, -22, -23, 26, -27, -28)
• TIMP-1, -2, -3, -4
Key points
• Intestinal microbiota maintains intestinal muco-
sal barrier function but may also impair barrier
function
• Intestinal microbiota may impact IBD pathogene-
sis/fibrosis;
• A dysbiosis occurs in IBD, which is different
between CD and UC;
• Serum markers for microbiota are associated with
fibrostenotic CD.
Questions
• The microbiota affects intestinal inflammation,
but does it affect fibrosis independently of inflam-
mation?
• Are there bacteria, or viruses, present in IBD that
promote fibrosis without inflammation?
• How do microbiotal products impact on myo-
fibroblast activation?
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receptors, but not all bacterial products are pro-fibrogenic.2
4.2. Genetic influences
Since microbial composition is established early in life, host
genetics may impact on bacterial composition and the
immune responses to commensal bacteria and mucosal
barrier function.52,53 The possible mechanisms for genetic
regulation of enteric microbiota include altered Paneth cell
function and expression of antimicrobial peptides, altered
mucus production, altered secretion of IgA and IgM, and
altered innate and adaptive immune responses.
Genes associated with CD include NOD2, that is linked to
α-defensin production and intracellular bacteria clearance,
ATG16L1, that is involved in autophagy and phagocytosis of
bacteria, neutrophil cytosolic factor 4 (NCF4) that is involved in
NADPH-mediated killing of phagocytosed bacteria, immunity-
related GTPase family M protein (IRGM), which impacts on
IFN-γ-induced killing of phagocytosed bacteria, and TLR4 that
modulates the immune response toward bacteria. NOD2
polymorphisms, with/without TLR and ATG16L1 polymor-
phisms, increase SB fibrostenosis20 (Fig. 4). Patients with a
stronger immune response to microbial peptides are also more
likely to develop earlier complicated CD.20
4.3. Microbiome effects
The persistence of exogenous, and endogenous stimuli,
provided by infectious pathogens are major promoters of
fibrosis.19 Thus an important role in fibrosis for the gut
microbiota is suggested.51 Unfortunately very few models can
study intestinal fibrosis in conjunction with the microflora.5
Although patients with NOD2 variants have more fibrosis, the
NOD2 knock-down animal models, or animals overexpressing a
variant corresponding to the humanmutations, do not develop
fibrosis.20 By contrast the spontaneous SAMP1/YitFc mouse
model of CD-like chronic ileitis demonstrates fibrosis and
these are abrogated under germ-free conditions.
There is thus doubt to the role of the microbiome in
fibrosis. One model used transplanted small intestine pieces
into the neck fold of the same, or another, rat strain with
TGF-β and other fibrosis mediators rapidly up-regulated and
fibrosis developing within three weeks.54 The same model in
mice confirmed the data but no differences in fibrosis
between WT and Myd88-deficient mice were found, indicating
that at least, under the artificial conditions of this model,
innate immune signalling was not central to the fibrosis.54
In liver fibrosis, impaired intestinal barrier function
occurs with increased bacterial wall product translocation
into the portal vein activating hepatic stellate cells (HSCs).55
Cystic fibrosis also was influenced by bacterial stimuli as
variants of the Cystic Fibrosis Transmembrane Resistance
Protein (CFTR) were associated with faecal microbiota
shifts, which aggravated the disease.56 These represent
clear examples of microbial contribution to fibrosis.
4.4. Conclusion
The IBD microbiota is different, and markers of microbiota
are associated with complicated CD. It is unknown, however,if these differences are cause or effect. Nor is it known if
they increase inflammation/fibrosis. It is thus important to
study the relationship between fibrosis and IBDmicrobiota and
determine if specific pro-fibrotic, or preventive microbial,
compositions exist. This needs to be done knowing that there
is huge variability in the human microbiome composition and
that genetic risk factors for IBD may shape the microflora
composition. Such studies will, therefore, need to be done in
large cohorts of phenotypically well-characterized patients.5. Adipose tissue
Adipose tissue is an energy regulator but also displays
advanced endocrine and immunological properties. The latter
occurs through its cellular composition that includes adipo-
cytes, but also preadipocytes, macrophages, lymphocytes,
fibroblasts and endothelial cells. These cells generate a dense
network of soluble factors that include adipokines, classical
cytokines, chemokines, growth factors and hormones.57 A role
for mesenteric adipose tissue (MAT), the white adipose tissue
(WAT) in IBD intestinal fibrosis is recognized.585.1. Creeping fat
In IBD, mesenteric fat is altered and may present as ‘creeping
fat’ or ‘fat wrapping’ while ‘mesenteric obesity’ can occur in
CD.57 ‘Creeping fat’ extends from themesentery and covers at
least 50% of the bowel circumference. These changes occur in
N50% of CD patients. It correlates with inflammation severity
with the terminal ileum most frequently involved. More
interestingly, abnormal collagen deposition and stricturing
are common findings in the bowel with fat wrapping
suggesting a relationship between adipose tissue and fibrosis.
Key points
• ‘Creeping fat’ or ‘fat wrapping’ is specific for CD;
• The terminal ileum is most frequently affected by
‘fat wrapping’;
• Intestinal fibrosis is associated with ‘creeping
fat’;
• Mesenteric adipose tissue contributes to pro-
inflammatory/fibrotic responses.
Questions
• What are the adipose-tissue derived pro-
inflammatory/fibrotic responses?
• What is the role of adipokines in fibrosis?
• Is there an adipose-tissue anti-fibrotic response?
• How do microbial factors elicit an immune and
pro-fibrotic response from adipose tissue?
• Can ‘creeping fat’ represent an anti-microbial
defense mechanism?
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Adipose tissue demonstrates unique functional characteris-
tics, which may contribute to inflammation and fibrosis in IBD.
Adipose tissue macrophages (ATMs) and T lymphocytes (ATTs)
from active IBD release more IL-6, IL-4 and IL-13 than inactive
disease and controls.59 A clear increase in the proportion of
‘alternatively activated’ or M2 macrophages is present in
creeping fat.60 M2 macrophages are involved in tissue repair
and collagen deposition.1 ATMs are under the constant
influence of locally produced soluble mediators including
adipokines.60 The functional importance of ATMs and ATTs,
and the potential association with fibrosis, however, remains
unclear.
Pro-inflammatory mediators stimulate M1 macrophages,
while M2 are polarised by Th2 cytokines. Epigenetic changes
and non-coding RNAs are involved in this process, as miR-155
diminishes IL-13-induced M2 polarisation through reducing
levels of IL-13. Mechanistic studies have demonstrated that
M2 macrophages are not required for a Th2 response.1
Arg1-expressing M2 cells are required for the suppression
and resolution of fibrosis as M2 cells compete with Th2 cells
and fibroblasts for L-arginine, which is required for the
production of L-proline and collagen.61 Rather than promot-
ing fibrosis, M2 cells inhibit ECM synthesis and fibrosis thus
their role in fibrosis requires further investigation.
5.3. Adipocytes and microbial translocation
As fibrosis may be triggered by bacterial-derived factors it is
important that adipocytes and preadipocytes bear function-
al PPRs, which elicit an immune response to microorganisms.
In addition, adipocytes may transform into macrophages and
exert direct anti-microbial activity. This suggests that fat
wrapping is an anti-microbial defense mechanism that
isolates affected bowel to contain intraluminal bacteria
spread and prevent bacterial translocation in mesenteric
adipocytes in CD.62 ‘Creeping fat’-induced intestinal fibrosis
could be a mechanism for preventing bacterial spread.
5.4. Adipocytes and adipokines
Adipocytes act as endocrine cells and, in IBD mesenteric
adipose tissue and serum, secrete active pro- and
anti-inflammatory molecules, known as adipocytokines or
adipokines including leptin, adiponectin, resistin and ghrelin.
Leptin is a cytokine-like protein that regulates immunity by
promoting a Th1 profile, thus impacting CD pathogenesis.57,58
Adiponectin has a similar structure to TNF-α and antagonizes
TNF-α by competing for the same receptor and demonstrates
anti-inflammatory activity. Adiponectin down-regulates inter-
cellular adhesion molecule-1 (ICAM-1), endothelial adhesion
molecule-1 (ECAM-1) and E-selectin, thus inhibiting inflamma-
tory cell migration and also regulates wound healing and
fibrosis.63 While leptin is profibrogenic, and liver fibrosis
is decreased in leptin- or leptin receptor deficient mice,
adiponectin is, by contrast, anti-fibrogenic as extensive liver
fibrosis may develop in adiponectin-knockout mice and is
alleviated by administration of recombinant adiponectin.63 A
potential anti-fibrotic effect of visceral mesenteric fat could
relate to adipocytokine autophagy regulation.High levels of C1q/TNF-related protein-3 (CTRP-3) ex-
pression occur in adipose tissue. CTRP3 is a paralog of
adiponectin and a member of the CTRP superfamily. It is
recognized as a novel adipokine widely expressed in CD.64
CTRP3 exerts anti-inflammatory/-fibrogenic effects in
human colonic fibroblasts inhibiting TGF-β release, reducing
CTGF expression and collagen production.
5.5. Adipocytes and PPARγ
Mesenteric fat's role in intestinal fibrosis correlates with
PPARγ activity.57,58 PPAR-γ affects inflammation/fibrosis in
IBD as its activation in visceral mesenteric fat reduces TNF-α
and leptin expression, while increasing adiponectin.65
PPARγ activators are efficacious in a variety of experimen-
tal models of fibrosis. Specific synthetic ligands for PPARγ
control fibrosis by down-regulating myofibroblasts prolifera-
tion and migration, and inducing apoptosis, inhibiting profi-
brogenic TGF-β, PDGF and leptin while up-regulating anti-
fibrogenic HGF and adiponectin, and reducing ECM deposi-
tion.16,63 The inhibitory effects of adiponectin are mediated
by AMP kinase activation. Moreover, genetic deletion of
adiponectin in mouse fibroblasts abrogated the TGF-β
signalling inhibition by PPARγ agonists. Together, it suggests
that the adiponectin/AMP kinase pathway is important in ECM
regulation and fibrosis.
The importance of crosstalk betweenmesenteric fat and IBD
intestine and its role in fibrogenesis is controversial. Further
investigations may allow for analysis of mechanisms involved in
fibrosis and point to potential anti-fibrotic strategies.6. Genetic and epigenetic factors
IBD fibrosis susceptibility may have genetic and/or epige-
netic components. IBD Genome-wide association studies
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ing single nucleotide polymorphism-SNP. In 2013 the number
of IBD risk loci was 163, whose 110 are shared between CD
and UC, 23 are specific for UC and 30 for CD.66 These
polymorphisms impact the innate immunity, autophagy,
intestinal barrier functions, IL-10 signalling and adaptive
immunity. Some of these polymorphisms may promote the
development of intestinal fibrosis.
These genetic variations, however, only account for approx-
imately 20% of IBD cases. Other geneticmechanisms, therefore,
may be involved, including heritable and reversible epigenetic
alterations, notably DNA methylation and histone modifica-
tion.66 In addition, miRNAs may affect IBD immunity and
fibrosis.36 There is thus a need to comprehensively characterize
the functional genomic features of IBD and the environmental
triggers together with specific disease phenotypes.6.1. Genetics
IBD fibrosis is dynamic and multifactorial and develops by
interactions between genetic and environmental factors with
different genetic polymorphisms influencing fibrosis in animal
models and human case–control studies. These suggest that
variants of genes encoding immunoregulatory proteins, pro-
and anti-inflammatory cytokines, and fibrogenic factors may
impact IBD fibrosis.6.1.1. NOD2
The NOD2 gene, on chromosome 16 was one of the first
genetic candidates involved in intestinal fibrosis. The three
variants of NOD2 gene (R702W, G908R, L1007fsinsC) con-
tribute as much as 30–50% of CD susceptibility.
There is a genotype/phenotype association between
NOD2 variants and fibrostenosing disease.20,67 A meta-
analysis identified that a single NOD2 variant increased the
risk for intestinal fibrosis by 8% and up to 41% for 2
variants.67 The combination of NOD2 variants and serolog-
ical markers were associated with complicated disease.20 A
large retrospective study of 1528 CD patients with N10 yrs
follow-up, detected increased probability of developing
stenosing disease with NOD2, Janus kinase (JAK)2 and
ATG16L1 mutations.68 Furthermore, CD patients carrying
NOD2 gene variants have an increased and early need for
first surgery due to stricturing disease and higher rate of
surgical recurrence.69
Themechanisms that are responsible for the NOD2-induced
fibrosis are unknown. This gene is important in intestinal
autophagy against microbes and, in combination ATG16L1 and
TLR variants, may contribute to the transcriptional and
translational changes causing fibrosis.70 Interaction between
different genes is also suggested with more fibrostenosing CD
in individuals carrying the NOD2 genotype and 4G/4G
genotype of plasminogen activator inhibitor (PAI-I).6.1.2. ATG16L1
Autophagy-related-16L1 gene (ATG16L1) variants (rs2241879
and rs2241880) favour fibrosis.68 Their impact, however,
varies between patients and regions, thus ATG16L1 may be
complementary to other gene mutations.6.1.3. TLRs
TLR variants, especially TLR4, are associated with increased
fibrostenotic SB CD.20,21 Multiple variants in TLR4 also result
in liver fibrosis, whereas a TLR7 SNP protects from advanced
liver inflammation and fibrosis.71
6.1.4. CX3CR1 gene
Two polymorphisms (V249I and T280M) of chemokine
fractalkine receptor CX3CR1 are associated with fibrostenotic
CD, particularly in smokers and this is independent of NOD2.72,73
6.1.5. TGF-β
TGF-β1 is the prototypical fibrogenic molecule, but although,
TGF-β1 polymorphisms are associatedwith stricturing CD, and a
shorter time to intestinal resection in adults,74 in children with
IBD, intestinal fibrosis was not linked to four different TGF-β
mutations.75
6.1.6. Interleukin 23 receptor
Variants in the interleukin 23 receptor (IL23R) gene are
associated with CD fibrosis, with the TT genotype of IL23R
rs1004819 variant associated with ileal and stricturing CD,
but like ATG16L1 there are geographical differences.76
6.1.7. MMPs and TIMPs
The balance between MMPs and TIMPs is vital in fibrosis. SNPs in
genes encodingMMP-1, -2, -3, -9, TIMP-1 have been described in
CD and the 5T5T genotype at the MMP-3 SNP-1613 5 T/6 T
increases the chance of stenotic complications in CD.77
6.2. Epigenetics
Epigenetics is the study of all heritable, and potentially
reversible, genome functional changes that do not alter the
nucleotide DNA sequence i.e. the regulation of gene
expression.66 Epigenetics can be further defined as ‘the
inheritance of variation above and beyond (epi)changes in
the DNA sequence’ and represents mechanisms by which the
environment may alter gene expression.
Various epigenetic mechanisms, including DNA methyla-
tion, histonemodifications (histonemethylation, acetyilation,
phosphorylation, sumoylation/ubiquitination) and formation
of particular chromatin structure, play crucial roles in the
gene transcriptional expression in ECM-producing cells.
ECM degradation is also regulated through epigenetic modu-
lation of matrix-associated enzymes. Epigenetic markers may
thus be the missing link connecting the IBD internal micro- and
external macro-environmental exposure to the transcriptome
changes associated with fibrosis. The epigenetic control of
inflammation and fibrosis, in IBD is not fully understood.
6.2.1. DNA methylation
Numerous intestinal disease-associated DNA-methylations
occur in IBD.78 Changes in methylation states of IBD-
associated genes are associated with gene expression shifts.
Specific methylation may be associated with IBD where
there are distinct DNA methylations profiles (1505 CpG sites
of 807 genes). One study identified seven CsG sites where
differential methylation occurred in IBD.78 Moreover, in IBD,
subtype-specific changes in DNA methylation occurs, identi-
fied in several loci within the IL-12/IL-23 pathway.79
Table 3 Experimental models to study IBD fibrosis.
Animal models CELL CULTURE SYSTEMS
Spontaneous Cell lines cultures
SAMP1/Yit mouse Human cell primary
1160 G. Latella et al.It is unknown, however, how these methylation profiles
impact on IBD genes. Demethylation of the MD-2 promotor
site in the TLR4/MD-2 complex results in increased MD-2
expression, while IFN-γ methylation levels correlate with
the immune response to microbial components.80,81cultures from IBD pts
Chemical-Induced Fibroblasts
2, 4, 6-trinitrobenzenesulphonic
acid (TNBS)
Myofibroblasts
Dextran sodium sulphate
(DSS)
Smooth muscle cells
Bacteria-Induced Endothelial cells
Salmonella Microvescicles
Escherichia coli
Peptidoglycan-polysaccharide
(PG-PS)
Immune-mediated6.3. Conclusion
Genetic variations are associated with CD fibrosis, and most
are associated with NOD2. Other mutations will, undoubt-
edly, be found, may clarify the complex characterisation
and subsequent changes in functional genomics. Epigenetic
studies in IBD, however, are in their infancy and future
studies may potentially have high clinical utility, especially
in the prediction of the future complication of intestinal
fibrosis and the impact of therapeutic interventions.Key points
• Genetic variants and IBD susceptibility are linked;
• NOD2 variants, alone or in combination with TLR
or ATG16L1 polymorphisms are associated with
fibrostenotic SB CD.
• Epigenetic modifications may amplify, or inhibit,
the fibrogenic processes.
Questions
• Which gene variants alter the risk of IBD fibrosis
and how?
• Which epigenetic modifications primarily affect
fibrosis?
• How does the gut microenvironment and the
external macroenvironment interact with the
genetic/epigenetic factors associated with intes-
tinal fibrosis?
Radiation-induced
Post-operative
Gene knockout and transgenic7. Animal models
Animal models are essential for dissecting the pathogenetic
mechanisms of inflammation-induced intestinal fibrosis. Un-
derstanding the similarities and differences between each
model and human disease is essential as, currently, no single
animal model truly recapitulates the chronic, fluctuating,
progressive nature of IBD.5
Animal models addressing intestinal fibrosis can be classi-
fied into seven categories: spontaneous, chemical-, bacterial-,
immune- and radiation-induced, post-operative and gene
knockout and transgenic models (Table 3). Besides the animal
models, several in vitro systems are also available.7.1. Spontaneous Intestinal Fibrosis
7.1.1. SAMP1/Yit mouse
The SAMP1/Yit mouse is the most representative model
of chronic intestinal inflammation, as disease developsspontaneously.82 Its similarities with CD include ileal
lesions, segmental and transmural injury, granulomas and
perianal lesions. Microbial factors accelerate, but are not
essential, for the model. A striking feature is prominent
hypertrophy of ileal muscularis propria with areas of focal
fibrosis that result in segmental stricturing and pre-stenotic
dilatation.
The mucosal immunophenotype of ileitis has two
distinct phases.83 The induction phase is a typical,
bacteria-related, Th1 response with no muscular hyper-
trophy or strictures. After week 10, the maintenance/
chronic phase is established and is dominated by Th2/IL-13
responses.83 Alterations in ECM occur with collagen
deposition and fibrostenosis. The SAMP1/Yit model offers
unique opportunities to study induction and perpetuation,
of inflammation-induced intestinal fibrosis.7.2. Chemically-induced models
The ‘chemical’ models of intestinal inflammation/fibrosis
are the most utilized because they are easy, reproducible
and straightforward. They involve colonic injury induced
by the local delivery of an offensive chemical and allow
for the study of both inflammatory and mucosal repair
mechanisms.
The mucosal events that follow a chemical insult are,
however, not representative of the immunological
phenomena in IBD and results should be analyzed with
caution.
7.2.1. TNBS
TNBS-induced colitis is the best-characterized murine model of
inflammation-induced intestinal fibrosis.45 Colorectal colonic
fibrosis, lumen stenosis and bowel dilatation develops after
several doses of TNBS. Fibrosis is associated with elevated
mucosal pro-inflammatory/fibrogenic factor expression and
1161Intestinal fibrosis in IBDmorphological analysis of colonic mesenchymal cells reveals
distinctive features and enhanced response to IFN-γ stimula-
tion, which primarily increase TIMP-1 expression.45
Mucosal expression of IL-13 replaces the initial Th1-type
response and induces TGF-β1 expression by week 8–9
post-TNBS administration. Abrogation of IL-13 signalling via
soluble IL-13Rα2-Fc, or IL-13Rα2-specific siRNA prevents
TGF-β1 upregulation and fibrosis.84 IGF-I and early growth
response gene (Egr)-1 are also pivotal in this model.
Fibrosis depends on the presence of inflammation as it is
effectively prevented by the prophylactic neutralization of
the master inflammatory regulator NF-κB45 and by the
coadministration of retinoic acid, while enhanced by the
co-administration of indomentacin.47
7.2.2. DSS
Dextran sodium sulphate (DSS) is administered in the drinking
water resulting in colonic injury followed by spontaneous
healing. Colonic fibrosis occurs after a single, or repeated
cycles, of DSS administration and is dependent upon the
murine genetic background.85 After 5 days of DSS administra-
tion, collagen colonic deposition is evident and gradually
increases with elevations of TGF-β1, MMP-2 and -9. This is
associated with mucosal upregulation of IFN-γ, TNF-α, IL-1β,
IL-6, IL-17a and IL-10 mRNA.86
7.3. Bacteria-induced models
7.3.1. Salmonella
Apost-Salmonella enteric serovar Typhimurium (S typhimurium)
infection fibrosis murine model was reported and character-
ized by caecal inflammation and fibrosis.87 At the molecular
level, TGF-β1 and its downstream mediator CTGF, and IGF-1
are upregulated in regions with infecting microorganisms. A
strong pro-inflammatory mucosal milieu, consisting of TNF-α,
IFN-γ, MCP-1, and IL-17 are also detected in infected ceca,
providing a link between inflammation and fibrosis. This
model demonstrates that inflammation precedes fibrosis and
more importantly that limiting inflammation by early inter-
vention limits fibrosis. When a certain pathological stage is
reached, however, fibrosis is independent of inflammation
and non-reversible. A serious drawback of this model is that
Salmonella infection does not result in fibrosis in humans.
7.3.2. Adherent-invasive Escherichia coli
Chronic adherent-invasive Escherichia coli infection in
streptomycin-treated conventional mice induces an active
T-helper 17 response, heightened levels of proinflammatory
cytokines and fibrotic growth factors, with the development
of transmural inflammation and fibrosis.88 Depletion of CD8+
T cells increases the caecal bacterial load and the level of
inflammation and intestinal fibrosis in C57BL/6 mice, suggest-
ing that they play a protective role. These findings suggest
that chronic adherent-invasive Escherichia coli infection
results in an immunopathology that is similar to that seen in
CD.
7.3.3. PG-PS
An intramural intestinal wall injection of peptidoglycan-
polysaccharide (PG-PS) induces local inflammation, follow-
ed by bowel wall thickening and fibrosis with increasedTGF-β1 and IGF-1 expression.89 Inflammation and fibrosis
are triggered by products of the commensal intestinal flora
and thus allows for the study of microbiota-induced fibrosis.
7.4. Immune-mediated models
The T-cell transfer model is the prototypical immune-mediated
model, where naive CD45RBhigh CD4+ T cells are injected into
SCID mice resulting in severe transmural colonic inflammation
and mild fibrosis.90 This model, however, has only been used
to examine the immune-mediated events and not fibrosis.
Since in IBD T cells are intimately involved in fibrosis,
investigation of fibrogenesis in this model should be of use.
7.5. Radiation-induced intestinal fibrosis
Radiation can cause bowel inflammation and fibrosis, which is
similar to CD with myofibroblast/SMC proliferation, vascular
sclerosis and chronic ulcers.91 Endothelial cell dysfunction is
key for radiation-induced intestinal fibrosis with prolonged
upregulation of fibrogenic cytokines in the irradiated bowel.
Ras homologue (Rho) and Rho-associated kinase (ROCK) sig-
nalling pathways are involved, as are mast cells and their
products.
7.6. Post-operative models of fibrosis
Postoperative anastomotic fibrosis is common, but why it
develops is unknown. In IL-10 KO mice following ileocecal
resection, inflammation-driven small intestinal fibrosis occurs
at the site of resection and adjacent SB.92 Interestingly,
germ-free IL-10 KO mice don't develop fibrosis, suggesting
a role for gut microbiota. As fibrosis occurs proximal to
anastomosis, it represents an excellent model for the study of
cellular and molecular mechanisms of this complication.
A new model is the heterotopic transplantation of SB
resections in rats.54 Rapid loss of crypt structures occurs at
day 2 after transplantation followed by lymphocyte infiltra-
tion and obliteration of the intestinal lumen by fibrosis at
day 21, which is associated with increased expression of
established mediators of fibrosis such as αvβ6 integrin,
IL-13, and TGF-β. Typical histologic and molecular features
of fibrosis are observed in the heterotopic intestinal grafts,
which suggests, that this new model could be instrumental in
studying treatment of intestinal fibrosis.
7.7. Gene knockout and transgenic models
The development of intestinal fibrosis by the manipulation
of selected genes represents a direct method for determin-
ing which specific immune abnormalities may lead to
fibrosis. IL-10-deficient mice develop chronic enterocoli-
tis.93 A typical Th1-dominant inflammatory cytokine appears
early, whereas in late disease a Th2 profile emerges
resulting in ECM accumulation. This model could be useful
to investigate mucosal fibroblasts in fibrosis.
As TGF-β/Smad signalling is important for fibrosis, disrup-
tion of TGFβ/Smad signalling reduces intestinal fibrosis.94
Forced intestinal overexpression of TGFβ1 by an adenoviral
vector results in inflammation/fibrosis, collagen deposition
events of intestinal fibrosis and to test new therapies?
• Do results need to be replicated in different animal
1162 G. Latella et al.and myofibroblast infiltration with colonic obstruction in 50%
of mice.95models?
• Are animal models useful to investigate early and
late events of intestinal fibrosis?
• Which in vitro models are more useful and reliable to
unravel the complex cellular and molecular mecha-
nisms of intestinal fibrosis?7.8. Conclusion
Animal models are integral to basic and translational
research. More importantly, novel anti-fibrotic therapies
can be tested by directly manipulating specific molecular
pathways. The inherent problems associated with such
approaches, however, should be kept in mind:1. No animal model truly represents human disease.
Chemical models lack the chronic nature, while genet-
ically manipulated models have single defects that do
not recapitulate the polygenetic nature and generalized
immune dysregulation. The few spontaneous models may
thus offer the best opportunity for dissecting the fibrotic
pathways.
2. As fibrosis primarily is a product of chronic inflamma-
tion, it is not easy to separate the anti-inflammatory
from anti-fibrotic effects of treatments.
3. The majority of models demonstrate a dependence on
TGF-β1 or IL-13 for fibrogenesis, but these aremost probably
complementary. It is not clear whether these are true
biological phenomena or reflect current fibrosis-related
research.
4. The natural history of each model needs to be consid-
ered. Different phases of inflammation should be
recognized, their immunological characteristics identi-
fied, and temporal and aetiological association with
fibrosis defined. For example, some models develop as
typical Th1-mediated inflammatory disease but with
chronicity shift towards a Th2/IL-13 predominant type
where fibrosis occurs. It may thus be more appropriate
that anti-fibrotic treatments aim at neutralizing the
late, and not the early, responses. By contrast, the exact
time-point at which fibrogenesis starts is not well
defined and it may be much earlier than thought,
suggesting that therapies used in parallel with anti-
inflammatory treatment may be appropriate.Key points
• There are few models of intestinal fibrosis;
• Most IBD animal studies have focused on immunity
and inflammation;
• No single animal model recapitulates human IBD;
• Similarities and differences between the models
and human IBD should be clearly delineated;
• Animal models represent indispensable tools;
• Findings in experimental models do not always
translated into clinical practice.
Questions
• Is a standard definition for intestinal fibrosis in
models required?
• Are animal models useful to identify pathogenic8. Conclusion
Intestinal fibrosis is highly complex with the specific molecules
determining the balance between physiologic repair and
excessive ECM accumulation remaining unknown. Strong evi-
dence indicates that inflammation triggers fibrosis, which, once
established, may progress independently. It is critical, there-
fore, to elucidate the cellular signals that promote fibrogenesis
and act independently of inflammatory pathways and the
immuno-inflammatory response. Defining the cellular and
molecular mechanisms involved in intestinal fibrosis is key to
the development of new therapies.
The concept of intestinal fibrosis has changed from being
static and irreversible to a dynamic and reversible disease.
Novel therapeutic strategies are under investigation to target
specific steps in fibrogenesis with the aim of reducing, or
reversing, IBD fibrosis. One hope is that researchers, funding
agencies and pharmaceutical industries accelerate their efforts
to identify, and develop, safe and effective anti-fibrotic
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